This recommendation is intended to provide a guideline for radiosynoviorthesis (RSO) in the effective local treatment of chronic inflammatory (non-infectious) joint diseases. It was developed in an interdisciplinary manner and describes the general objectives, definitions, clinical background information, indication and contraindications of this radionuclide therapy. The requirements to be met by a treatment center, the results of pretherapeutic examinations as well as recommendations on how the treatment should be carried out. Here, organizational and technical issues have been considered. Furthermore, information on the surveillance and follow-up of the treated patients can be found. In general, treatment and follow-up should be done in in close cooperation of the participating disciplines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-1324-4745 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Atrial Fibrillation and Oral Anticoagulation Status in Health-Related Quality of Life 12 Months After Ischemic Stroke or TIA.
Brain Behav
January 2025
Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Aims: Atrial fibrillation (AF) accounts for about 20% of all ischemic strokes worldwide. It is known that AF impairs health-related quality of life (HRQOL) in the general population, but data on HRQOL in stroke patients with newly diagnosed AF are sparse.
Methods: Post hoc analysis of the prospective, investigator-initiated, multicenter MonDAFIS study (NCT02204267) to analyze whether AF-related oral anticoagulation (OAC), and/or AF-symptom severity are associated with HRQOL after ischemic stroke or transient ischemic attack (TIA).
Diosgenin loaded-chitosan biodegradable nanoparticles ameliorate adjuvant-induced arthritis, pain, and peripheral neuropathy through moderation of inflammatory and oxidative stress biomarkers.
Int J Biol Macromol
December 2024
Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore Campus, Lahore 38000, Pakistan. Electronic address:
This research work was designed to develop efficient Diosgenin (DGN) loaded biodegradable nanoparticles (DGN-NPs) for treating rheumatoid arthritis. The DGN-NPs were synthesized by ionic-gelation method using chitosan as a biodegradable polymer and in-vitro release study was performed followed by kinetics study. DGN-NPs had an average size of 290 nm, zeta potential of +11.
View Article and Find Full Text PDFContext-dependency of the REM sleep behavior disorder screening questionnaire - Clinical utility under scrutiny.
Parkinsonism Relat Disord
January 2025
Cognitive Neuroscience, Institute for Neuroscience and Medicine, INM-3, Research Centre Juelich, Juelich, Germany; Medical Psychology | Neuropsychology and Gender Studies, Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Electronic address:
Introduction: The REM Sleep Behavior Disorder (RBD) Screening Questionnaire (RBDSQ) is a widely established screening tool for detecting isolated RBD (iRBD). However, its accuracy may depend on its application context, e.g.
View Article and Find Full Text PDFValidation Study of the Parkinson's Disease Stigma Questionnaire (PDStigmaQuest).
J Parkinsons Dis
October 2024
Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Background: Stigma is a relevant aspect of Parkinson's disease (PD). Specific stigma tools are needed to address the complex construct of stigma in PD comprehensively.
Objective: To test the dimensionality and psychometric properties of the newly developed Parkinson's Disease Stigma Questionnaire (PDStigmaQuest).
Background: Oral anticoagulation (OAC) is key in stroke prevention in patients with atrial fibrillation (AF) but there is uncertainty regarding the optimal timing of OAC (re)initiation after stroke, as recent large randomised controlled trials have methodological weaknesses and excluded stroke patients on therapeutic anticoagulation at stroke onset as well as patients started on a vitamin K antagonist after stroke. The '1-3-6-12 days rule', based on expert consensus and referring to stroke severity, was used in clinical practice to initiate OAC after acute ischaemic stroke or transient ischaemic attack (TIA) since publication in 2013.
Methods: We retrospectively assessed whether compliance to the '1-3-6-12 days rule' was associated with the composite endpoint (recurrent stroke, systemic embolism, myocardial infarction, major bleeding or all-cause death).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!